Figure 1: Response rates with first-line atezolizumab in the BIRCH trial, according to PD-L1 expression status
19.01.2017 | SCLC | Online-Artikel
19.01.2017 | SCLC | Online-Artikel
Figure 1: Response rates with first-line atezolizumab in the BIRCH trial, according to PD-L1 expression status